Literature DB >> 25067994

Statistical Methods for Selecting Maximum Effective Dose and Evaluating Treatment Effect When Dose - Response is Monotonic.

Maiying Kong1, Shesh N Rai1, Roberto Bolli2.   

Abstract

The maximum effective dose (MaxED) is an important quantity for therapeutic drugs. The MaxED for therapeutic drugs is defined as the dose above which no improvement in efficacy is obtained. In this article, we propose two experimental designs and analytic methods (one single-stage design and one two-stage design) to select the MaxED among several fixed doses and to compare the therapeutic effect of the selected MaxED with a control. The selection of MaxED is based on the isotonic regression under the restriction of monotonicity. In the single-stage design, both the selection of the MaxED and assessing its efficacy are carried out at the end of experiment. In the two-stage design, the selection of the MaxED and assessment of its efficacy are carried out at the interim analysis (first stage), the experiment in the second stage is carried out only at the selected MaxED and control if the first-stage test is not significant. Thus, the two-stage design enables selection of the MaxED at an earlier stage and stopping the trial earlier if the treatment effect at MaxED is extreme. Williams' test (1972) is applied to test whether the selected MaxED is significantly different from control for the single-stage design and the first-stage test of the two-stage design. The sample size calculation for each design is provided. Extensive simulations are carried out to illustrate the performances of the proposed methods.

Entities:  

Keywords:  O’Brien and Fleming’s repeated significance test; Two-stage design; Williams’ test

Year:  2014        PMID: 25067994      PMCID: PMC4110746          DOI: 10.1080/19466315.2013.826596

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  17 in total

1.  Combining multiple comparisons and modeling techniques in dose-response studies.

Authors:  F Bretz; J C Pinheiro; M Branson
Journal:  Biometrics       Date:  2005-09       Impact factor: 2.571

2.  Ordered multiple comparisons with the best and their applications to dose-response studies.

Authors:  K Strassburger; F Bretz; H Finner
Journal:  Biometrics       Date:  2007-05-08       Impact factor: 2.571

3.  Adaptive dose finding based on t-statistic for dose-response trials.

Authors:  Anastasia Ivanova; James A Bolognese; Inna Perevozskaya
Journal:  Stat Med       Date:  2008-05-10       Impact factor: 2.373

4.  Multiple test procedures for dose finding.

Authors:  A C Tamhane; Y Hochberg; C W Dunnett
Journal:  Biometrics       Date:  1996-03       Impact factor: 2.571

5.  Estimating the maximum effective dose in a quantitative dose-response experiment.

Authors:  M D Remmenga; G A Milliken; D Kratzer; J R Schwenke; H R Rolka
Journal:  J Anim Sci       Date:  1997-08       Impact factor: 3.159

6.  The comparison of several dose levels with a zero dose control.

Authors:  D A Williams
Journal:  Biometrics       Date:  1972-06       Impact factor: 2.571

Review 7.  Dose response studies. II. Analysis and interpretation.

Authors:  S J Ruberg
Journal:  J Biopharm Stat       Date:  1995-03       Impact factor: 1.051

8.  Monitoring multi-armed trials.

Authors:  M A Proschan; D A Follmann; N L Geller
Journal:  Stat Med       Date:  1994 Jul 15-30       Impact factor: 2.373

9.  A comparison of two phase I trial designs.

Authors:  E L Korn; D Midthune; T T Chen; L V Rubinstein; M C Christian; R M Simon
Journal:  Stat Med       Date:  1994-09-30       Impact factor: 2.373

10.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

View more
  1 in total

1.  Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.

Authors:  Beibei Guo; Yisheng Li
Journal:  BMC Med Res Methodol       Date:  2014-07-29       Impact factor: 4.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.